Cargando…
Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcrip...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/ https://www.ncbi.nlm.nih.gov/pubmed/29156698 http://dx.doi.org/10.18632/oncotarget.18583 |
_version_ | 1783279411110346752 |
---|---|
author | Moreno, Natalia Holsten, Till Mertins, Julius Zhogbi, Annabelle Johann, Pascal Kool, Marcel Meisterernst, Michael Kerl, Kornelius |
author_facet | Moreno, Natalia Holsten, Till Mertins, Julius Zhogbi, Annabelle Johann, Pascal Kool, Marcel Meisterernst, Michael Kerl, Kornelius |
author_sort | Moreno, Natalia |
collection | PubMed |
description | Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT. |
format | Online Article Text |
id | pubmed-5689588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56895882017-11-17 Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors Moreno, Natalia Holsten, Till Mertins, Julius Zhogbi, Annabelle Johann, Pascal Kool, Marcel Meisterernst, Michael Kerl, Kornelius Oncotarget Research Paper Rhabdoid tumors are caused by the deletion of SMARCB1, whose protein encodes the SMARCB1 subunit of the chromatin remodeling complex SWI/SNF that is involved in global chromatin organization and gene expression control. Simultaneously inhibiting the main players involved in the deregulated transcription machinery is a promising option for preventing exaggerated tumor cell proliferation and survival as it may bypass compensatory mechanisms. In support of this hypothesis, we report efficient impairment of cellular proliferation and strong induction of cell death elicited by inhibition of bromodomain protein BRD4 and transcription kinase CDK9 using small molecular compounds. Combination of both compounds efficiently represses antiapoptotic genes and the oncogene MYC. Our results provide a novel approach for the treatment of RT. Impact Journals LLC 2017-06-21 /pmc/articles/PMC5689588/ /pubmed/29156698 http://dx.doi.org/10.18632/oncotarget.18583 Text en Copyright: © 2017 Moreno et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Moreno, Natalia Holsten, Till Mertins, Julius Zhogbi, Annabelle Johann, Pascal Kool, Marcel Meisterernst, Michael Kerl, Kornelius Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title_full | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title_fullStr | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title_full_unstemmed | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title_short | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
title_sort | combined brd4 and cdk9 inhibition as a new therapeutic approach in malignant rhabdoid tumors |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/ https://www.ncbi.nlm.nih.gov/pubmed/29156698 http://dx.doi.org/10.18632/oncotarget.18583 |
work_keys_str_mv | AT morenonatalia combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT holstentill combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT mertinsjulius combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT zhogbiannabelle combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT johannpascal combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT koolmarcel combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT meisterernstmichael combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors AT kerlkornelius combinedbrd4andcdk9inhibitionasanewtherapeuticapproachinmalignantrhabdoidtumors |